MedTrace Logo

EVITA: Evaluation of VIP Feature in Pacemaker Patients

NCT00366158 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 461

Last updated 2019-02-04

No results posted yet for this study

Summary

The primary efficacy objective of this clinical investigation is to demonstrate that the Ventricular Intrinsic Preference (VIP™) feature allows to reduce the medium- and long-term incidence of unnecessary ventricular pacing in patients with intact AV conduction.

Conditions

Interventions

DEVICE

Device: St. Jude Medical Victory dual-chamber pacemaker

Pacemaker implant

DEVICE

Ventricular Intrinsic Preference

Programming of pacemaker

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Alexander Bauer, MD · Universitätskliniken Heidelberg, Heidelberg, 69115, Germany

  • Charles Kennergren, MD · Sahlgrenska University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2009-06-30
Completion
2010-09-30

Countries

  • Germany
  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00366158 on ClinicalTrials.gov